Is Fenofibrate a Reasonable Treatment for Diabetic Microvascular Disease?

Rafael Simó, Olga Simó-Servat, Cristina Hernández

Research output: Contribution to journalReview articleResearchpeer-review

11 Citations (Scopus)


© 2015, Springer Science+Business Media New York. Type 2 diabetes is a pandemic disease, and its prevalence is increasing mainly due to an increase in obesity and life expectancy. Diabetic complications and their comorbidities constitute the most important economic cost of the disease and represent a significant economic burden for the healthcare systems of developed countries. Despite improving standards of care, people with diabetes remain at risk of the development and progression of microvascular diabetic complications. Therefore, the identification of novel therapeutic approaches is necessary. The aim of this article is to provide an overview of the clinical benefits of fenofibrate on microvascular diabetic complications, with special emphasis on diabetic retinopathy. In addition, the potential mechanisms of action will be briefly discussed.
Original languageEnglish
JournalCurrent Diabetes Reports
Issue number5
Publication statusPublished - 1 Jan 2015


  • Clinical studies
  • Diabetes
  • Diabetic nephropathy
  • Diabetic neuropathy
  • Diabetic retinopathy
  • Experimental studies
  • Fenofibrate


Dive into the research topics of 'Is Fenofibrate a Reasonable Treatment for Diabetic Microvascular Disease?'. Together they form a unique fingerprint.

Cite this